Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer is yes, in one specific situation. Mounjaro (tirzepatide) is licensed in the UK for adults with a BMI of 30 or above, but the licence also covers adults with a BMI of 27 or above when at least one weight-related health condition is present. So a BMI below 30 does not automatically rule you out — it depends on what else is in your medical picture. These are prescription-only medicines, and a GPhC-registered prescriber makes the final call after a full clinical assessment, not a number on a scale alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro's UK marketing authorisation sets two routes in. Adults with a BMI of 30 or higher can be considered regardless of other conditions. Adults with a BMI between 27 and 29.9 can be considered if they have at least one weight-related comorbidity. The conditions that count include type 2 diabetes, prediabetes, hypertension, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and osteoarthritis, among others. This is the standard the prescriber applies, not a rigid cut-off that rejects anyone at 29.8.
A question our prescribers hear most weeks is whether having one of these conditions is enough on its own to qualify at a lower BMI. The honest answer is that meeting the licensed criteria is necessary but not sufficient: the prescriber still has to judge whether treatment is appropriate given your full health history, any contraindications, and your goals. The SmPC, published on the Electronic Medicines Compendium, sets out the full list of contraindications and special warnings that inform that review.
It is also worth knowing that for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK clinical guidance commonly applies thresholds around 2.5 kg/m² lower, so a BMI of 27.5 rather than 30 as the general starting point. The BMI thresholds for Mounjaro page covers those adjustments in more detail.
Many people searching this question have already looked at NHS eligibility and been told they do not qualify. That is understandable confusion, because NICE's recommended threshold for NHS tirzepatide (TA1026, published December 2024) sits well above the licensed minimum: a BMI of 35 or above plus at least one weight-related comorbidity, with the phased rollout currently prioritising people with four or more qualifying conditions. The NHS route is also restricted to specific care settings.
Private prescribing operates against the licensed criteria, not the NICE commissioning threshold. That gap matters. Someone with a BMI of 28 and well-controlled hypertension would not meet the current NHS criteria, but could be a reasonable candidate for private tirzepatide, subject to prescriber assessment. If you want to understand exactly what BMI you need for Mounjaro under each pathway, that page maps both routes side by side.
The private route also has no waiting list. A regulated online pharmacy like nume, with its own GPhC-registered pharmacy (registration 9012878, verifiable at the GPhC register), can complete a clinical consultation and dispatch treatment the same day if a prescriber approves it, without a GP referral. That is what makes the private route attractive for people who meet the licensed criteria but fall short of NHS thresholds.
If you are trying to work out whether you could take Mounjaro with a sub-30 BMI, the decision really has three parts. First, do you have at least one qualifying weight-related condition that has been diagnosed? A prescriber will want to see evidence of this, not a self-report. Second, are there any contraindications (for instance, a personal or family history of medullary thyroid carcinoma, MEN2, or a history of pancreatitis) that would make the medicine unsuitable regardless of BMI? Third, is the clinical risk-benefit balance favourable given your overall health?
That last point is where the assessment becomes genuinely clinical rather than administrative. Our page on using Mounjaro with a BMI under 30 explores how that risk-benefit review tends to play out in practice, including what comorbidity evidence a prescriber typically looks for. A BMI of 28 with poorly controlled type 2 diabetes and hypertension presents a different picture from a BMI of 28 with well-managed, stable hypertension and no other complications. Both might technically meet the licensed criteria; neither is an automatic approval. You can read more about getting Mounjaro with a BMI of 27 if that is your specific situation, or explore the broader Mounjaro treatment information to understand how the prescribing process works from start to finish.
One practical note: if you are considering treatment and your BMI sits just below 30, it is worth having your relevant health records to hand before your consultation. Documented diagnoses make the assessment faster and the clinical picture clearer for the prescriber reviewing your case, and our guide to the BMI needed to get Mounjaro sets out exactly which numbers apply to which route. The weight-loss treatment overview explains what to expect at each stage.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.